Sign up online today & collaborate
or click here to find out more
Endo International plc Announces Pricing of Private Offering of Senior Secured Notes12/04/2017Endo International plc (NASDAQ: ENDP) ("Endo") today announced that Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (collectively, the "Issuers"), its wholly-owned subsidiaries, priced $300 million aggregate principal amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount in connection with their previously announced private offering.
Disruption is the new normal 03/05/2017We live in an age of change where technology is allowing markets to move with breathtaking speed. Radical disruption is now a given. Companies that fail to expect and embrace it are left behind. Global brands that have grown spectacularly in recent years – such as AirBnB and Uber – have come from nowhere to transform entire sectors with their revolutionary approaches. Their ability to innovate – in terms of both products and the busin
Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases 05/05/2017Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases Summit Therapeutics plc('Summit', or the 'Company')PHASE 2 CoDIFy TRIAL RESULTS PUBLISHED IN LANCET INFECTIOUS DISEASES WITH DATA SHOWING SUMMIT'S RIDINILAZOLE ACHIEVED STATISTICAL SUPERIORITY OVER VANCOMYCIN IN THE TREATMENT OF C. DIFFICILE INFECTIONOxford, UK, 2 May 201
Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and Views’.11/05/2017Biotherapeutics News & Views FEATURE Fully human antibodies for therapeutic application – a promise fulfilled from great expectations? It is now 15 years since the FDA approved the first fully human monoclonal antibody (adalimumab, Humira®), heralding a new era in biotherapeutics. Fast forward to 2017, has their promise been realised? In this first issue of Biother
Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA Therapeutics03/05/2017Potential acquisition tied to clinical milestones of lead candidate MTL-CEBPA, a novel small activating RNA therapeutic in Phase 1/2a development in advanced liver cancerSosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) and MiNA Therapeutics Limited (“MiNA”) announced today that the companies have entered into a definitive agreement under which Sosei will